Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11077068 | SUNOVION PHARMS INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(1 year, 7 months ago) | |
US9931305 | SUNOVION PHARMS INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(1 year, 7 months ago) | |
US10888499 | SUNOVION PHARMS INC | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
Feb, 2022
(1 year, 7 months ago) | |
US9855221 | SUNOVION PHARMS INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(1 year, 7 months ago) | |
US8663687 | SUNOVION PHARMS INC | Film compositions for delivery of actives |
Feb, 2023
(7 months ago) | |
US8765167 | SUNOVION PHARMS INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(4 months from now) | |
US8603514 | SUNOVION PHARMS INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(6 months from now) | |
US10821074 | SUNOVION PHARMS INC | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
US9283219 | SUNOVION PHARMS INC | Sublingual films |
Jun, 2030
(6 years from now) | |
US9669021 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US9669019 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US10420763 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US9326981 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US9044475 | SUNOVION PHARMS INC | Sublingual apomorphine |
Jun, 2030
(6 years from now) | |
US8846074 | SUNOVION PHARMS INC | Sublingual films |
Dec, 2031
(8 years from now) | |
US8414922 | SUNOVION PHARMS INC | Sublingual films |
Dec, 2031
(8 years from now) | |
US11419769 | SUNOVION PHARMS INC | Sublingual films |
Dec, 2031
(8 years from now) | |
US10959943 | SUNOVION PHARMS INC | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(12 years from now) | |
US10449146 | SUNOVION PHARMS INC | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(12 years from now) |
Kynmobi is owned by Sunovion Pharms Inc.
Kynmobi contains Apomorphine Hydrochloride.
Kynmobi has a total of 19 drug patents out of which 5 drug patents have expired.
Expired drug patents of Kynmobi are:
Kynmobi was authorised for market use on 21 May, 2020.
Kynmobi is available in film;sublingual dosage forms.
Kynmobi can be used as treatment of 'off' episodes in patients with parkinson's disease.
The generics of Kynmobi are possible to be released after 19 April, 2036.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM;SUBLINGUAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic